GPT and familial hypercholesterolemia: The most common treatment-related adverse events included cytokine release syndrome (53.13%), leukopenia (43.75%), elevated alanine aminotransferase (43.75%), neutropenia (37.5%), constipation (31.25%), elevated aspartate aminotransferase (28.13%), decreased appetite (18.75%), Lung infections (15.63%), hypercholesterolemia (15.63%), fatigue (15.63%), hiccup (12.5%), nausea (12.5%), hypertriglyceridemia (12.5%) and anemia (12.5%).